Pre-made Mogamulizumab benchmark antibody ( Whole mAb, anti-CCR4 therapeutic antibody, Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mogamulizumab biosimilar, Whole mAb, Anti-CCR4 Antibody: Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[1] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and S¨¦zary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.
| Products Name (INN Index) | Pre-Made Mogamulizumab biosimilar, Whole mAb, Anti-CCR4 Antibody: Anti-CKR4/K5-5/CD194/CMKBR4/ChemR13/CC-CKR-4/HGCN:14099 therapeutic antibody |
|---|---|
| INN Name | Mogamulizumab |
| Target | CCR4 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Amgen,Bristol-Myers Squibb,Kagoshima University Dental School,Kyowa Hakko,Kyowa Hakko Kirin,Ono Pharmaceutical |
| Conditions Approved | Adult T-cell leukaemia-lymphoma,Cutaneous T-cell lymphoma,Peripheral T-cell lymphoma,Mycosis fungoides,Sezary syndrome,Mycosis fungoides |
| Conditions Active | Spinal cord disorders |
| Conditions Discontinued | Non-small cell lung cancer,Asthma,Hypersensitivity,Solid tumours |
| Development Tech | POTELLIGENT Technology |
| Previous Name | NA |
| Gm Offical Target Name | CCR4 |
| Package |
